Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
Oxysterols are a class of molecules derived from cholesterol via oxidation or as byproducts of cholesterol synthesis. Despite ...
The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to ...
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback